Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2004-03-29
2009-06-23
Shiao, Rei-tsang (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S397000, C514S399000, C548S311100, C548S300100
Reexamination Certificate
active
07550496
ABSTRACT:
Hypoxia-activated prodrugs can be used to treat cancer when administered alone or in combination with one or more anti-neoplastic agents.
REFERENCES:
patent: 3652579 (1972-03-01), Hoffer et al.
patent: 4908356 (1990-03-01), Borch et al.
patent: 4921963 (1990-05-01), Skov et al.
patent: 4945102 (1990-07-01), Suzuki et al.
patent: 5190929 (1993-03-01), Borch et al.
patent: 5270330 (1993-12-01), Suzuki et al.
patent: 5306727 (1994-04-01), Borch et al.
patent: 5403932 (1995-04-01), Borch et al.
patent: 5472956 (1995-12-01), Borch et al.
patent: 5622936 (1997-04-01), Wiessler et al.
patent: 5703080 (1997-12-01), Nakakura et al.
patent: 5750782 (1998-05-01), Denny et al.
patent: 5780585 (1998-07-01), Anlezark et al.
patent: 5872129 (1999-02-01), Denny et al.
patent: 5877158 (1999-03-01), Bosslet et al.
patent: 5985909 (1999-11-01), Denny et al.
patent: 6020315 (2000-02-01), Bosslet et al.
patent: 6130237 (2000-10-01), Denny et al.
patent: 6218519 (2001-04-01), Kenten et al.
patent: 6240925 (2001-06-01), McMillan et al.
patent: 6251933 (2001-06-01), Denny et al.
patent: 6506739 (2003-01-01), Herr et al.
patent: 6656926 (2003-12-01), Borch et al.
patent: 6855695 (2005-02-01), Lin et al.
patent: 2003/0008850 (2003-01-01), Borch et al.
patent: 2003/0050331 (2003-03-01), Ng et al.
patent: 2003/0096743 (2003-05-01), Senter et al.
patent: 2003/0130189 (2003-07-01), Senter et al.
patent: 2004/0121940 (2004-06-01), De Groot et al.
patent: 2004/0176332 (2004-09-01), Borch et al.
patent: 2004/0254103 (2004-12-01), Lin et al.
patent: 2005/0043244 (2005-02-01), Lin et al.
patent: 2229223 (1973-02-01), None
patent: 648 503 (1995-04-01), None
patent: 312 858 (1998-03-01), None
patent: WO 97/39007 (1997-10-01), None
patent: WO 00/64864 (2000-11-01), None
patent: WO 02/96910 (2002-12-01), None
patent: WO 04/85361 (2004-10-01), None
patent: WO 04/85421 (2004-10-01), None
Garsky publication, J. Med. Chem., 44(24), 4216-4224, 2001 (Abstarct only).
Berry et al., “5-Nitrofuran-2-ylmethyl group as a potential bioreductively activated pro-drug system,”J. Chem. Soc. Perkin Trans., 1:1147-1156 (1997).
Borch et al., “Synthesis and Evaluation of Nitroheterocyclic Phosphoramidates as Hypoxia-Selective Alkylating Agents,”J. Med. Chem., 43:2258-2265 (2000).
Borch et al., “Antitumor Activity and Toxicity of Novel Nitroheterocylic Phosporamidates,”J. Med. Chem., 44:74-77 (2001).
De Groot et al., “Anticancer Prodrugs for Application in Monotherapy: Targeting Hypoxia, Tumor-Associated Enzymes, and Receptors,”Current Medical Chemistry, 8:1093-1122 (2001).
De Jaeger et al., “Relationship of hypoxia to metastatic ability in rodent tumours,”Br. J. Cancer, 84(9):1280-1285 (2001).
Engle et al., “31P NMR Kinetic Studies of the Intra- and Intermolecular Alkylation Chemistry of Phosphoramide Mustard and Cognate N-Phosphorylated Derivatives ofN ,N-Bist(2-chlorethyl)amine1.2,”J. Med. Chem., 25:1347-1357 (1982).
Everett et al., “Modifying rates of reductive elimination of leaving groups from indolequinone prodrugs: a key factor in controlling hypoxia-selective drug release,”Biochemical Pharmacology, 63:1629-1639 (2002).
Everett et al., “Bioreductively-Activated Prodrugs for Targeting Hypoxic Tissues: Elimination of Aspirin from 2-Nitroimidazole Derivatives,”Biooganic Med. &Chem. Ltrs., 9:1267-1272 (1999).
Hay et al., “A 2-Nitroimidazole Carbamate Prodrug of 5-Amino-1-(Chloromethyl)-3-[(5,6,7-Trimethoxyindol-2-YL)Carbonyl]-1,2-Dihydro-3H[E]Indole (Amino-Seco-CBI-TMI) for Use With Adept and Gdept,”Biooganic Med. & Chem. Ltrs., 9:2237-2242 (1999).
Hay et al., “Structure-Activity Relationships of 1,2,4-Benzotriazine 1,4-Dioxides as Hypoxia-Selective Analogues of Tirapazamine,”J. Med. Chem., 46:169-182 (2003).
Hernick et al., “Design, Synthesis, and Biological Evaluation of Indolequinone Phosphoramidate Prodrugs Targeted to DT-diaphorase,”J. Med. Chem., 45:3540-3548 (2002).
Hernick et al., “Studies on the Mechanisms of Activation of Indolequinone Phosphoramidate Prodrugs,”J. Med. Chem., 46:148-154 (2003).
Kyle et al., “Direct Assessment of Drug Penetration into Tissue Using a Novel Application of Three-Dimensional Cell Culture,”Cancer Research, 64:6304-6309 (2004).
Lin et al., “(o- andp- Nitrobenzyloxycarbobyl)- 5-fluorouracil Derivatives as Potential Conjugated Bioreductive Alkylating Agents,”J. Med. Chem., 29:84-89 (1986).
Naylor et al., “Recent Advances in Bioreductive Drug Targeting,”Mini Reviews in Med. Chem., 1:17-29 (2001).
Papot et al., “Design of Selectively Activated Anticancer Prodrugs: Elimination and Cyclization Strategies,”Curr. Med. Chem.—Anti-Cancer Agents, 2:155-185 (2002).
Parveen et al., “2-Nitroimidazol-5-Ylmethyl as a Potential Bioreductively Activated Prodrug System: Reductively Triggered Release of the Parp Inhibitor 5-Bromoisoquinolinone,”Biooganic Med. &Chem. Ltrs., 9:2031-2036 (1999).
Rofstad et al., “Hypoxia-induced metastasis of human melanoma cells: involvement of vascular endothelial growth factor-mediated angiogenesis,”Br. J. Cancer, 80(11):1697-1707 (1999).
Rosen et al., “Phase 1 Study of TLK286 (Telcyta) Administered Weekly in Advanced Malignancies,”Clin. Cancer Res., 10:3689-3698 (2004).
Steinberg et al., “Synthesis and Evaluation of Pteroic Acid-Conjugated Nitroheterocyclic Phosphoramidates as Folate Receptor—Targated Alkylating Agents,”J. Med. Chem., 44:69-73 (2001).
Wakselman, M., “1,4- and 1,6- Eliminations from Hydroxy- and Amino-Substituted Benzyl Systems: Chemical and Biochemical Applications, ”Nouv. J. Chim., 7(7):439-447 (1983).
West et al., “A comparison of adriamycin and mAMSA, II. Studies with V79 and human tumour multicellular spheroids,”Cancer Chemother. Pharmacol., 20:109-114 (1987).
Workman et al., “The experimental development of bioreductive drugs and their role in cancer therapy,”Cancer and Metastasis Rev., 12:73-82 (1993).
Denny, W. A., “Prodrug strategies in cancer therapy,”Eur. J. Med. Chem., 36:577-595 (2001).
Lee et al., “Synthesis and Hypoxia-Selective Cytotoxicity of a 2-Nitroimidazole Mustard,”Bioorganic&Med . Chem. Ltrs., 8:1741-1744 (1998).
Duan Jian-Xin
Matteucci Mark
Rao Photon
Kaster Kevin
Rao Photon
Shiao Rei-tsang
Termes Lance A.
Threshold Pharmaceuticals, Inc.
LandOfFree
Compositions and methods for treating cancer does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Compositions and methods for treating cancer, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compositions and methods for treating cancer will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4145555